Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder

NCT06584942 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT06584942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06584942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder
Lead sponsor
Massachusetts General Hospital
Phase
Phase 4
Overall status
Completed
Start date
March 10, 2025
Completion date
June 11, 2026
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cannabis use disorder, cue-reactivity, functional mri, orexin antagonist